Abstract-The aim of the present study was to determine the effects and molecular mechanisms by which AMP-activated protein kinase (AMPK) regulates smooth muscle contraction and blood pressure in mice. In cultured human vascular smooth muscle cells, we observed that activation of AMPK by 5-aminoimidazole-4-carboxamide 1-␤-D-ribofuranoside inhibited agonist-induced phosphorylation of myosin light chain (MLC) and myosin phosphatase targeting subunit 1 (MYPT1). Conversely, AMPK inhibition with pharmacological or genetic means potentiated agonist-induced the phosphorylation of MLC and MYPT1, whereas it inhibited both Ras homolog gene family member A and Rho-associated kinase activity. In addition, AMPK activation or Rho-associated kinase inhibition with Y27632 abolished agonist-induced phosphorylation of MLC and MYPT1. Gene silencing of p190-guanosine triphosphataseactivating protein abolished the effects of AMPK activation on MLC, MYPT1, and Ras homolog gene family member A in human smooth muscle cells. Ex vivo analyses revealed that agonist-induced contractions of the mesenteric artery and aortas were stronger in both AMPK␣1 Ϫ/Ϫ and AMPK␣2 Ϫ/Ϫ knockout mice than in wild-type mice. Inhibition of Rho-associated kinase with Y27632 normalized agonist-induced contractions of AMPK␣1 Ϫ/Ϫ and AMPK␣2
A MP-activated protein kinase (AMPK) is a key component of an energy-sensing/signaling system that allows cells to sense changes in their energy status. 1,2 AMPK consists of 3 subunits, designated ␣, ␤, and ␥. The ␣ subunit contains the catalytic kinase domain, which transfers phosphate from ATP to the target protein. Phosphorylation of Thr 172 on the ␣ subunit by upstream signaling kinases activates AMPK, 3 and AMP allosterically promotes phosphorylation of this residue. 4 Activated AMPK phosphorylates a number of target proteins, resulting in increased glucose uptake, increased metabolism, and increased fatty acid oxidation. At the same time, AMPK activation inhibits hepatic lipogenesis, cholesterol synthesis, and glucose production. 5 Because AMPK activation has beneficial metabolic consequences for patients with metabolic syndrome and diabetes mellitus, it is a new target for the treatment of obesity and type 2 diabetes mellitus. 6 Recent studies found that AMPK-mediated cellular functions have protective effects that counteract many cardiovascular diseases. [7] [8] [9] [10] In addition, both 5-aminoimidazole-4-carboxamide 1-␤-D-ribofuranoside [AICAR] , an AMPK agonist) and resveratrol (a botanical phytoallexin AMPK agonist) are reported to lower blood pressure (BP) in insulinresistant and obese rats. 11, 12 However, these studies did not establish the direct effects of AMPK on BP, because AMPK activation is known to improve insulin resistance and metabolic anomalies in these models. Whether AMPK regulates vascular tone and/or BP remains unknown. Because vessel smooth muscle function is directly related to vascular tone, 13 and abnormal vascular smooth muscle cell (VSMC) relaxation or contraction is known to induce hypertension in both humans and animal models, 14 we hypothesized that activation of AMPK activation might lower BP by inhibiting vessel contraction. The aim of the present study was to elucidate the mechanisms by which AMPK activation attenuates agonist-induced contraction of smooth muscle and the physiological functions of AMPK in the regulation of BP in mice.
Methods and Materials
A full description of materials, animals, and methods used, including cell culture, gene transfection of cells, transfection of smallinterfering RNA (siRNA) into cells, Western blot analysis, rhotekin pull-down assay for Ras homolog gene family, member A (RhoA) activation, Rho-associated kinase (ROCK) activity assay, measurement of vessel tension in mice, BP measurement, and statistical analysis can be found in the online Data Supplement. Please see http://hyper.ahajournals.org.
Results

AICAR Inhibits Agonists-Induced Myosin Light Chain Phosphorylation in a Time-and Dose-Dependent Manner
Vessel tone is determined by the status of myosin light chain (MLC) (phosphorylation or dephosphorylation at ser19) in VSMCs. 15 We first determined whether AMPK activation could affect phenylephrine (PE)-induced phosphorylation of MLC. To test this, we treated human smooth muscle cell (HSMC) with agonists and measured MLC phosphorylation by immunoblot analysis. Treatment of HSMC with PE (1 mol/L, 30 minutes) significantly increased the phosphorylation of MLC ( Figure 1A and 1B) and AMPK phosphorylation at Thr 172 ( Figure S1A and S1B, available in the online Data Supplement). As expected, pretreatment with AICAR (2 mmol/L) increased PE-induced AMPK-Thr 172 phosphorylation in a time-and dose-dependent manner in HSMCs ( Figure S1A and S1B). However, AICAR pretreatment abolished PE-induced MLC phosphorylation ( Figure 1A and 1B) .
Next, to investigate whether AICAR pretreatment altered MLC phosphorylation caused by other agonists, we assayed the effects of AICAR on PE-unrelated agonist-induced MLC phosphorylation in HSMCs. As depicted in Figure 1C Importantly, AICAR significantly lowered U46619-or IBOPenhanced MLC phosphorylation.
PE-Induced MLC Phosphorylation Is Dependent on AMPK
To exclude potential off-target effects of AICAR, we next investigated whether genetic inhibition of AMPK by adenovirus-mediated expression of dominant-negative AMPK (AMPK-DN) affected PE-induced MLC activation. As expected, PE induced MLC phosphorylation in green fluorescent protein-expressing control HSMCs ( Figure  1D ). In AMPK-DN-expressing HSMCs, PE-induced MLC phosphorylation was greater than those in green fluorescent protein-expressing cells; conversely, MLC phosphorylation was absent in AMPK-constitutively active (CA)-expressing HSMCs ( Figure 1D ). Taken together, these data suggest that AMPK negatively regulates PE-induced MLC activation.
To investigate the roles of endogenous AMPK␣ in MLC phosphorylation, HSMCs that had been transfected with AMPK␣-specific siRNA or primary MSMCs isolated from AMPK␣1 Ϫ/Ϫ or AMPK␣2 Ϫ/Ϫ mice were exposed to PE. Western blot analysis revealed that either AMPK␣1-or ␣2-targeted siRNA reduced the levels of AMPK␣1 or ␣2, respectively ( Figure S2A ). As shown in Figure 1E , PEinduced MLC phosphorylation was greater in cells receiving AMPK␣1 or AMPK␣2-targeted siRNA than in wildtype (WT) or nontargeted control siRNA-transfected cells. Consistently, PE-induced MLC phosphorylation was significantly higher in AMPK␣1-or ␣2-null cells compared with those in WT cells ( Figure 1F (Figure 2A and 2B). Conversely, either AICAR treatment or AMPK-CA expression attenuated PE-induced MYPT1 phosphorylation. The effects of AMPK inhibition on PE-induced MYPT1 phosphorylation were further confirmed by siRNA-mediated AMPK␣ knockdown and gene-specific knockout mice. Knockdown of AMPK␣1 or ␣2 by siRNA significantly increased PE-induced MYPT1 phosphorylation at Thr 696 ( Figure 2C ). Similarly, MYPT1 phosphorylation at Thr696 was significantly higher in VSMCs isolated from AMPK␣1 or ␣2 when compared with those in WT cells ( Figure  2D ). Taken together, these data indicate that AMPK negatively regulates Thr 696 phosphorylation of MYPT1, an upstream regulator of MLC.
ROCK Participates in the Regulation of MYPT1 by AMPK
The ROCK-dependent signal pathway is essential in mediating agonists-induced smooth muscle vessel contrac- tion. 16, 17 We next determined the effect of the ROCK inhibitor, Y27632, on MYPT1 phosphorylation. As shown in Figure 3A , Y27632 treatment reversed both PE-and U46619-induced MYPT1 phosphorylation in HSMCs, implying that ROCK mediates PE-and U46619-induced MYPT1/MLC activation.
It was important to determine the effects of AMPK on ROCK activity. To this end, ROCK activity was assayed in cells treated with AICAR (AMPK activator) or compound C (AMPK inhibitor). As depicted in Figure 3B , AICAR reversed PE-induced ROCK activity, whereas compound C enhanced this activity. Consistently, genetic activation of AMPK by overexpressing AMPK-CA significantly lowered PE-induced up-regulation of ROCK activity ( Figure 3C ), whereas AMPK-DN enhanced PE-induced upregulation of ROCK activity. Overall, these data suggest that PE-induced ROCK activation is AMPK dependent.
AMPK Negatively Regulates PE-Induced RhoA Activation
Smooth muscle MYPT1 is a G protein-regulated enzyme. 18 RhoA belongs to the Ras low-molecular-weight G protein superfamily. RhoA binds GTP to activate ROCK, and this in turn leads to MYPT1 phosphorylation, MLC activation, and smooth muscle cell contraction. As shown in Figure 3D and 3E, both PE and U46619 activated RhoA by increasing the amount of GTP-bound RhoA. AICAR inhibited RhoA activation, but compound C increased its activation. These results were confirmed by transduction of cells with AMPK-CA or AMPK-DN and measurement of the RhoA activation status. PE-induced RhoA activation was lower in AMPK-CA-expressing cells that in green fluorescent protein-expressing control cells ( Figure  3F) ; however, AMPK-DN enhanced PE-induced RhoA activation. Thus, these data suggest that PE-induced RhoA activation is AMPK dependent. 
Activation of AMPK Promotes the Binding of p190-GTP-Activating Protein to RhoA in Agonist-Stimulated VSMCs
RhoA cycles between an active GTP-bound state and an inactive GDP-bound state through nucleotide exchange and intrinsic guanosine triphosphatase activity. The RhoA activation status is controlled by guanine nucleotide exchange factors 19 and p190-GTP-activating proteins (GAPs). We tested whether AMPK inactivates RhoA by promoting the association of RhoA with p190-GAP. We found that the binding of p190-GAP to RhoA was significantly increased by AICAR (2 mmol/L) in PEstimulated HSMC, but inhibition of AMPK with compound C (20 mol/L) significantly decreased RhoA/p190-GAP complex formation ( Figure 4A ). Overexpression of AMPK-CA mimicked the effect of AICAR on p190-GAP/RhoA binding in PE-treated HSMCs ( Figure 4B) . Similarly, the effect of compound C was mimicked by overexpression of AMPK-DN or AMPK␣ knockdown using AMPK␣-specific siRNA ( Figure 4B and 4C) . Taken together, these data suggest that activation of AMPK promotes the binding of p190-GAP to RhoA in agonist-stimulated HSMCs.
p190-GAP Silencing Abolishes AICAR Suppression of RhoA Activation, MYPT1 Phosphorylation, and MLC Phosphorylation in VSMCs
To establish whether p190-GAP mediated the effects of AMPK␣ on RhoA inactivation, VSMCs were transfected with p190-GAP-targeted siRNA or nontargeted control siRNA. Silencing of p190-GAP expression was confirmed by Western blot analysis ( Figure S2B ). As expected, in PE-stimulated HSMC cells that were transfected with nontargeted control siRNA, AICAR treatment significantly reduced the levels of active RhoA ( Figure 4D ), phosphorylated MYPT1 ( Figure 4E ), and phosphorylated MLC ( Figure 4F ). In contrast, gene silencing of p190-GAP abolished the effects of AICAR, implying that p190-GAP is required for AMPK-mediated RhoA inhibition.
Inhibition of AMPK Potentiates Agonist-Induced Contraction of Mesenteric and Aortic Vessels in Mice
Because peripheral resistance is determined by the contractile status of VSMCs in small arterioles, 20 we then determined vascular smooth muscle function in resistance vessels from WT, AMPK␣1 Ϫ/Ϫ , and AMPK␣2 Ϫ/Ϫ mice. Both PE and U46619 were used to induce contraction of mouse mesenteric artery ring explants in an organ bath ( Figure S3A and S3B). Both PE and U46619 significantly increased mesenteric artery contraction in WT, AMPK␣1
Ϫ/Ϫ , and AMPK␣2
Ϫ/Ϫ explants. However, explants from AMPK␣1 Ϫ/Ϫ mice had a stronger mesenteric artery contraction force than explants from WT mice, which is in line with an earlier report. 21 Explants from AMPK␣2 Ϫ/Ϫ mice also had a stronger mesenteric artery contraction force than explants from WT mice. In addition, AMPK deletion also enhanced the contraction of conduit vessels in mouse aortas ( Figure S4A ).
Next, we determined the effect of AICAR (a potent AMPK activator) or compound C (a potent AMPK inhibitor) on PE-induced contraction of aortic rings. Vessel rings were pretreated with AICAR (2 mmol/L) or compound C (20 mol/L) for 2 hours, and contractions were then induced by PE, as above. Vessel contraction was significantly inhibited by AICAR but was increased by compound C ( Figure  S4B ). These data suggest that activated AMPK suppresses agonist-induced vasoconstriction.
AMPK␣-Deletion-Enhanced Vessel Contraction Is ROCK Dependent
Next, we tested whether ROCK mediates the effect of AMPK on vessel contraction. Aortas and mesenteric arteries from AMPK␣1 Ϫ/Ϫ and AMPK␣2 Ϫ/Ϫ mice were pretreated with Y27632 (2 mol/L) for 30 minutes, and this significantly inhibited agonist-induced increases in contraction ( Figure  S3A and S3B and Figure S4C ). These data show that inhibition of AMPK potentiates agonist-induced contraction of murine conduit and resistance vessels, likely through regulation of ROCK.
Deletion of AMPK Suppresses p190-GAP Serine Phosphorylation and Binding to RhoA In Vivo
p190-GAP activity is regulated in a serine or tyrosine phosphorylation-dependent manner. 22 We hypothesized that AMPK, which is a serine/threonine kinase, directly phosphorylates p190-GAP. Because no site-specific phosphoserine p190-GAP antibodies are available, we relied on immunoprecipitation of total p190-GAP and then Western blot analysis using a general phosphoserine antibody ( Figure 5 ). Immunoprecipitation isolated p190-GAP in cells from WT mice was detected by the phosphoserine antibody; however, deletion of either AMPK␣1 or ␣2 dramatically suppressed the serine phosphorylation of p190-GAP ( Figure 5A ), suggesting that AMPK␣ deletion may suppress p190-GAP activity by preventing its phosphorylation. In addition, deletion of AMPK␣1 or ␣2 also inhibited the binding of RhoA by p190-GAP ( Figure 5B ), and this, in turn, increased RhoA activation ( Figure 5C ).
Y27632-Inhibitable Hypertension in AMPK␣2
؊/؊ Mice
We reported previously that AMPK␣1 Ϫ/Ϫ mice exhibit splenomegaly and moderate anemia 23 and were, therefore, not suitable for BP studies. Thus, we determined the systolic BP, diastolic BP, and mean BP in WT and AMPK␣2 Ϫ/Ϫ mice. As depicted in Figure 6A , all of the BP measurements (systolic BP, diastolic BP, and mean BP) in AMPK␣2 Ϫ/Ϫ mice were higher than those in WT mice under basal conditions. Importantly, Y27632 (10 mg/kg, 4 hours, given IP) significantly reduced the BP values ( Figure 6A , systolic BP, diastolic BP, and mean BP), ROCK activity ( Figure 6B ), MYPT1 phosphorylation ( Figure 6C ), and MLC phosphorylation ( Figure 6D ) in AMPK␣2 Ϫ/Ϫ mice. Collectively, these data indicate that upregulation of the p190-GAPdependent RhoA/ROCK/MYPT1/MLC pathway contributes to hypertension in AMPK␣2 Ϫ/Ϫ mice.
Discussion
The major finding of this study is that AMPK activation lowers BP by suppressing VSMC contractility via the inhibition of MYPT1/MLC phosphorylation. Mechanistically, we found that AMPK decreases VSMC contractility by inhibiting p190-GAP-dependent RhoA activation. One of the most important findings of this study is that AMPK activation suppresses VSMC contractility by inhibiting MYPT1/MLC phosphorylation. This appears to occur indirectly through MYPT1-Thr 696 dephosphorylation, which, in turn, inhibits MLC phosphatase activity. This conclusion is supported by several findings. First, deletion of AMPK␣1 or ␣2 enhanced agonist-induced contraction in explanted murine mesenteric arteries, and inhibition of AMPK with a pharmacological inhibitor (compound C) reproduced this effect. Second, activation of AMPK by AICAR attenuated agonistinduced contraction. Third, systemic BP was higher in AMPK␣2 Ϫ/Ϫ mice than in WT mice under normal physiological conditions. Although AMPK␣1 Ϫ/Ϫ mice were excluded from this study because knockout of this gene results in splenomegaly and moderate anemia, 23, 24 we expect that the hypertensive phenotype observed in the AMPK␣2 Ϫ/Ϫ mice would also be observed in AMPK␣1 Ϫ/Ϫ mice. Finally, AMPK-CA or AICAR treatment abolished PE-induced phosphorylation of MYPT1 at Thr 696 and MLC at Ser 19 . Conversely, AMPK-DN or compound C treatment potentiated PE-induced activation of MYPT1 and MLC. Taken together, our results support a direct inhibitory effect of AMPK on VSMC contractility.
RhoA/ROCK signaling plays an important role in cell proliferation, cell cycle progression, and cell survival after vascular injury. 25 Because AMPK activation promotes the binding of p190-GAP to RhoA and in this way blocks RhoA activity, AMPK might also be important for other physiological processes, such as angiogenesis or tube formation after vascular damage, in which RhoA/ROCK signaling is involved. 26 This finding is consistent with a recent study demonstrating that the AMPK activator, AICAR, inhibits ROCK activity in osteoblastic cells in a dose-dependent manner. 27 The regulation of the RhoA/ROCK pathway by AMPK appears to be cell type dependent. It has been shown recently that AMPK activation enhances MLC phosphorylation through the RhoA/ROCK signaling pathway in epithelial cells. 28 Taken together, these studies support a novel mechanism of AMPK action whereby activation of AMPK suppresses the PE-induced signaling pathway by reducing RhoA/ ROCK activity via p190-GAP. This, in turn, inhibits MYPT1/ MLC phosphorylation in smooth muscle cells, leading to decreased vessel contraction ( Figure S5 ). In combination, these effects contribute to the regulation of BP in mice.
Perspectives
Activation of the RhoA/ROCK cell signaling pathway is known to play an essential role in hypertension. 29 Thus, inhibition of RhoA/ROCK by AMPK might be an important mechanism for lowering BP. In addition to its suppression of VSMC contractility, AMPK can also lower BP by improving NO bioactivity and endothelial cell function. AMPK might increase NO release by increasing phosphorylation and activation of endothelial NO synthase at Ser1177 and Ser633 or by decreasing NO inactivation by reactive oxygen species. Indeed, there is a growing body of evidence that supports the notion that AMPK suppresses reactive oxygen species from mitochondria and/or NADPH oxidase. 9, 30 Interestingly, depressed AMPK activation, or AMPK deregulation, has been observed in arteries of rodent models where vascular dysfunction exists, including in streptozotocin-induced diabetes, Zucker diabetic fatty rats, aged rats, and Otsuka Long Evans Tokushima Fatty rats. 31 In addition, adiponectin-AMPK signaling becomes depressed in insulinsensitive tissues of hypertensive rats. 32 Consistently, AMPK activation by AICAR or resveratrol lowered BP in insulin-resistant and obese rats. 11, 12 Importantly, metformin, one of the mostly widely used antidiabetic drugs that is reported to activate AMPK in vivo, is reported to lower BPs in various models of hypertensive animals and in patients with or without diabetes mellitus. Interestingly, recent studies report that telmisartan and losartan, selective angiotensin II receptor blockers, are reported to inhibit VSMC proliferation 33 and glucose uptake by activating AMPK. 34 Taken together, AMPK inhibition might contribute to the initiation and progression of hypertension, and AMPK is a novel therapeutic target for effective treatments of hypertension, especially in metabolic syndromes such as obesity and diabetes mellitus.
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